Feed NVCR
NV

NovoCure NVCR · NASDAQ

$14.68 -2.78% (-$0.42)

Market cap
$1.73B
Enterprise value
$1.87B
P/E
-
Forward P/E
-
PEG
-
P/S
2.5x
P/FCF
-
EV/EBITDA
-
ROIC
-26.2%
Gross margin
76.1%
Net margin
-21.2%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.99
Free float
82.8%

About the company

NovoCure Limited is an international biotechnology company specializing in the development of innovative therapies for cancer treatment. The company is known for its unique Tumor Treating Fields (TTFields) technology, which uses electric fields to target and treat tumors, inhibiting their growth. TTFields is a non-invasive treatment that is used for various types of cancer, including brain cancer, lung cancer, and more. NovoCure focuses on providing new therapeutic approaches that can improve treatment outcomes and the quality of life for patients suffering from cancer.

Sector

Healthcare

Industry

Medical - Devices

CEO

Frank Leonard

Employees

1,605

Headquarters

Baar

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy